Skip to content

A retrospective study on the treatment of acute myocardial infarction complicated with cardiogenic shock by Deng's Wendan Decoction combined with IABP

A retrospective study on the treatment of acute myocardial infarction complicated with cardiogenic shock by Deng's Wendan Decoction combined with IABP

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001984
Enrollment
Unknown
Registered
2025-10-22
Start date
2025-09-22
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction complicated with cardiogenic shock

Interventions

Control group:There is coronary intervention +IABP treatment + conventional treatment (standardized Western medical drug treatment: including antiplatelet aggregation drugs, statins, nitrates, fluid r
organ function support such as ventilators)
Pogejiuxin Decoction Group:There are coronary intervention +IABP treatment + conventional treatment + Deng's Wendan Decoction treatment. Deng's Warming Gallbladder Decoction Ingredients: 10g of Bamboo

Sponsors

University Town, Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Meet the AMICS diagnostic criteria for both traditional Chinese and Western medicine; 2) All patients underwent coronary intervention and IABP treatment.; 3) Age range: 18 to 85 years old; 4) The materials are complete as a whole.

Exclusion criteria

Exclusion criteria: 1)Patients with acute gastrointestinal bleeding, cerebral hemorrhage, malignant tumors, aortic dissection, pulmonary embolism, acute infection, etc. 2) CS not caused by AMI, such as myocarditis, arrhythmia, structural heart diseases, etc. 3) The treatment involves the intervention of other traditional Chinese medicines and Chinese patent medicines. 4) Patients who died on the day of admission; 5) Insufficient data and follow-up failure.

Design outcomes

Primary

MeasureTime frame
28-day mortality;

Secondary

MeasureTime frame
Cardiac color Doppler ultrasound cardiac function;Mechanical assistance time, vasoactive drug time;The rehospitalization rate, MACE events and mortality rate within one year of follow-up;Total length of hospital stay and total cost;left ventricular ejection fraction (LVEF) of surviving patients after treatment;

Countries

China

Contacts

Public ContactZhuang Jieqin

Emergency Department, University Town, Guangdong Provincial Hospital of Traditional Chinese Medicine

1004548400@qq.com+86 137 6065 3929

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026